Results 181 to 190 of about 321,481 (292)

Population pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin‐resistant tuberculosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Moxifloxacin is a priority drug for treating rifampicin‐resistant tuberculosis (RR‐TB). We assessed the pharmacokinetics of a child‐friendly, dispersible 100 mg tablet moxifloxacin formulation (dispersed in water) compared to the standard 400 mg non‐dispersible formulation (crushed and suspended in water) in children and evaluated current dosing ...
Megan Palmer, Yuanxi Zou, Anneke C. Hesseling, Louvina van der Laan, Ingrid Courtney, Aarti A. Kinikar, Naresh Sonkawade, Mandar Paradkar, Vandana Kulkarni, Dessa Jean O. Casalme, Melchor V. G. Frias, Heather Draper, Lubbe Wiesner, Mats O. Karlsson, Paolo Denti, Elin M. Svensson, Anthony J. Garcia‐Prats   +16 more
wiley   +1 more source

Unexpected Zoonotic and Hybrid Schistosome Egg Excretion Patterns, Malawi, 2024. [PDF]

Emerg Infect Dis
O'Ferrall AM, Kayuni SA, Cunningham LJ, Makaula P, Archer J, Roberts AP, Musaya J, Stothard JR.   +7 more
europepmc   +1 more source

Assessment of ethnic differences in pharmacokinetics and clinical responses of acalabrutinib between Chinese and White patients with B‐cell malignancies

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims The aim of this study was to assess differences between Chinese and White patients in pharmacokinetics (PK) of, and clinical response to, acalabrutinib and its pharmacologically active major metabolite, ACP‐5862, to support recommended dosing in Chinese patients with B‐cell malignancies.
Tingting Yao, Junjie Ding, Shringi Sharma, Yunfei Li, Qianwei Xu, Peiming Ma   +5 more
wiley   +1 more source

Toxicokinetics of a Single Oral Dose of Aflatoxin B₁ in Plasma, Feces, and Urine of Male Donkeys. [PDF]

Toxins (Basel)
Feng Y, Li M, Zheng Y, Qu H, Li P, Dong B, Wang Y, Liu G, Jia B, Ma Q.   +9 more
europepmc   +1 more source

Oral paltusotine, a nonpeptide selective somatostatin receptor 2 agonist: Mass balance, absolute bioavailability and metabolism in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Paltusotine is a novel, nonpeptide, selective somatostatin receptor 2 agonist in development for the treatment of acromegaly and carcinoid syndrome. This study investigated the mass balance, routes of excretion, absolute bioavailability and metabolite profile of orally administered paltusotine.
Rosa Luo, Ajay Madan, Christine T. Ferrara‐Cook, Deepak Dalvie, Lance Goulet, R. Scott Struthers, Alan S. Krasner   +6 more
wiley   +1 more source

Presence of Potential Enteropathogenic Bacteria in Cats and Association With Diarrhea in Multicat Households. [PDF]

J Vet Intern Med
Bogedale K, Klein-Richers U, Felten S, Bergmann M, Pantchev N, Zablotski Y, Suchodolski J, Busch K, Unterer S, Hartmann K.   +9 more
europepmc   +1 more source

Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase‐1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose study

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Dipeptidyl peptidase‐1 (DPP‐1) inhibitors have been studied for the treatment of neutrophil‐mediated inflammatory diseases including bronchiectasis, bronchial asthma and cystic fibrosis. This study evaluated the pharmacokinetics, pharmacodynamics, safety and tolerability of DPP‐1 inhibitor HSK31858 in healthy Chinese volunteers.
Yuhao Wang, Chao Yu, Mengyue Hu, Lu Wang, Meixia Chen, Hanmo Liu, Nan Wu, Jie Hou   +7 more
wiley   +1 more source

Preparation of Fecal Microbiota Transplantation Products for Companion Animals. [PDF]

PLoS One
Randolph NK, Salerno M, Klein H, Diaz-Campos D, van Balen JC, Winston JA.   +5 more
europepmc   +1 more source

Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim TAS5315 is a Bruton tyrosine kinase (Btk) inhibitor in development for autoimmune and allergic diseases, including rheumatoid arthritis (RA) and chronic spontaneous urticaria (CSU). Two clinical studies evaluated the pharmacology and safety of single and multiple oral doses of TAS5315.
Yuji Kumagai, Tomoe Fujita, Mika Maeda, Akiko Yamamoto, Hideki Amano   +4 more
wiley   +1 more source

Sodium Retention in Large Herbivores: Physiological Insights and Zoogeochemical Consequences. [PDF]

J Exp Zool A Ecol Integr Physiol
Abraham AJ, Duvall ES, Doughty CE, Riond B, Ortmann S, Terranova M, le Roux E, Clauss M.   +7 more
europepmc   +1 more source